SNGLR Capital
SNGLR Capital is a venture capital firm established in 2021 and located in Zug, Switzerland. The firm focuses on investing in early-stage technology startups primarily in Europe, targeting sectors with high growth potential such as longevity, smart mobility, and smart cities. SNGLR Capital emphasizes the use of advanced technologies, including artificial intelligence, blockchain, data (IoT and APIs), 5G, and robotics, to support its investment strategy. The firm collaborates closely with entrepreneurs throughout their journey, leveraging the experience of its team, which includes former founders, early-stage investors, and advisors. Additionally, SNGLR Capital engages with selected corporate venture units and consulting firms to enhance market access and provide technology insights through its XLabs development program.
1 past transactions
Cellestia
Venture Round in 2021
Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.